CD137
CD137+ T cells
Immune checkpoint inhibitors
Immunotherapy
MDSCs
NSCLC
Pembrolizumab
Soluble immune checkpoints
Tregs
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
03 Apr 2024
03 Apr 2024
Historique:
received:
05
02
2024
accepted:
28
03
2024
medline:
4
4
2024
pubmed:
4
4
2024
entrez:
3
4
2024
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICIs), administered alone or combined with chemotherapy, are the standard of care in advanced non-oncogene addicted Non-Small Cell Lung Cancer (NSCLC). Despite these treatments' success, most long-term survival benefit is restricted to approximately 20% of patients, highlighting the need to identify novel biomarkers to optimize treatment strategies. In several solid tumors, immune soluble factors, the activatory CD137 The levels of T cells, MDSCs and soluble factors were evaluated in 89 metastatic NSCLC patients who underwent ICIs as first- or second-line treatment. T cell analysis was performed by cytoflurimetry evaluating Tregs and different CD137 In both groups of patients, high levels of circulating CD137 High levels of CD137
Sections du résumé
BACKGROUND
BACKGROUND
Immune checkpoint inhibitors (ICIs), administered alone or combined with chemotherapy, are the standard of care in advanced non-oncogene addicted Non-Small Cell Lung Cancer (NSCLC). Despite these treatments' success, most long-term survival benefit is restricted to approximately 20% of patients, highlighting the need to identify novel biomarkers to optimize treatment strategies. In several solid tumors, immune soluble factors, the activatory CD137
METHODS
METHODS
The levels of T cells, MDSCs and soluble factors were evaluated in 89 metastatic NSCLC patients who underwent ICIs as first- or second-line treatment. T cell analysis was performed by cytoflurimetry evaluating Tregs and different CD137
RESULTS
RESULTS
In both groups of patients, high levels of circulating CD137
CONCLUSION
CONCLUSIONS
High levels of CD137
Identifiants
pubmed: 38570798
doi: 10.1186/s12967-024-05142-6
pii: 10.1186/s12967-024-05142-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
329Subventions
Organisme : Sapienza Università di Roma
ID : RM12117A7B767D0D
Organisme : Sapienza Università di Roma
ID : RP122181610A7266
Organisme : Sapienza Università di Roma
ID : RM12117A85361029
Organisme : Sapienza Università di Roma
ID : RM120172B803DB14
Organisme : Sapienza Università di Roma
ID : RM120172B40A805A
Organisme : Sapienza Università di Roma
ID : RM123188C3F3E706
Organisme : Sapienza Università di Roma
ID : RM123188C3F3E706
Organisme : Ministero dell'Università e della Ricerca
ID : 2022K5RYF5
Informations de copyright
© 2024. The Author(s).
Références
Herbst R, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553:446.
doi: 10.1038/nature25183
pubmed: 29364287
Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:339.
doi: 10.1016/j.annonc.2022.12.009
pubmed: 36872130
Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro CJ, et al. Five-year outcomes from the randomized, phase III trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2021;39:723.
doi: 10.1200/JCO.20.01605
pubmed: 33449799
pmcid: 8078445
Herbst RS, Garon EB, Kim DW, Cho BC, Gervais R, Perez-Gracia JL, et al. Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC. J Thorac Oncol. 2021;16:1718.
doi: 10.1016/j.jtho.2021.05.001
pubmed: 34048946
Mazieres J, Rittmeyer A, Gadgeel S, Hida T, Gandara DR, Cortinovis DL, et al. Atezolizumab versus docetaxel in pretreated patients with NSCLC: final results from the randomized phase 2 POPLAR and phase 3 OAK clinical trials. J Thorac Oncol. 2021;16:140.
doi: 10.1016/j.jtho.2020.09.022
pubmed: 33166718
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823.
doi: 10.1056/NEJMoa1606774
pubmed: 27718847
Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078.
doi: 10.1056/NEJMoa1801005
pubmed: 29658856
Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381:2020.
doi: 10.1056/NEJMoa1910231
pubmed: 31562796
Mezquita L, Preeshagul I, Auclin E, Saravia D, Hendriks L, Rizvi H, et al. Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. Eur J Can. 2021;151:211.
doi: 10.1016/j.ejca.2021.03.011
Sánchez-Gastaldo A, Muñoz-Fuentes MA, Molina-Pinelo S, Alonso-García M, Boyero L, Bernabé-Caro R. Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab. Transl Lung Can Res. 2021;10:2509.
doi: 10.21037/tlcr-21-156
Jiang M, Peng W, Pu X, Chen B, Li J, Xu F, et al. Peripheral blood biomarkers associated with outcome in non-small cell lung cancer patients treated with nivolumab and durvalumab monotherapy. Front Oncol. 2020;10:913.
doi: 10.3389/fonc.2020.00913
pubmed: 32695663
pmcid: 7339928
Kamphorst AO, Pillai RN, Yang S, Nasti TH, Akondy RS, Wieland A, et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc Natl Acad Sci USA. 2017;114:4993.
doi: 10.1073/pnas.1705327114
pubmed: 28446615
pmcid: 5441721
Kim HR, Park SM, Seo SU, Jung I, Yoon HI, Gabrilovich DI, et al. The ratio of peripheral regulatory T cells to Lox-1+ polymorphonuclear myeloid-derived suppressor cells predicts the early response to AntiPD1 therapy in patients with non-small cell lung cancer. Am J Respir Crit Care Med. 2019;199:243.
doi: 10.1164/rccm.201808-1502LE
pubmed: 30339766
pmcid: 6835091
Zizzari IG, Di Filippo A, Botticelli A, Strigari L, Pernazza A, Rullo E, et al. Circulating CD137+ T cells correlate with improved response to Anti-PD1 immunotherapy in patients with cancer. Clin Cancer Res. 2022;28:1027.
doi: 10.1158/1078-0432.CCR-21-2918
pubmed: 34980602
pmcid: 9377756
Cirillo A, Zizzari IG, Botticelli A, Strigari L, Rahimi H, Scagnoli S, et al. Circulating CD137+ T cell levels are correlated with response to pembrolizumab treatment in advanced head and neck cancer patients. Int J Mol Sci. 2023;24:7114.
doi: 10.3390/ijms24087114
pubmed: 37108276
pmcid: 10138766
Ye Q, Song DG, Poussin M, Yamamoto T, Best A, Li C, et al. CD137 accurately identifies and enriches for naturally occurring tumor reactive T cells in tumor. Clin Cancer Res. 2014;20:44.
doi: 10.1158/1078-0432.CCR-13-0945
pubmed: 24045181
Hejleh TA, Furqan M, Ballas Z, Clamon G. The clinical significance of soluble PD-1 and PD-L1 in lung cancer. Crit Rev Oncol Hematol. 2019;143:148.
doi: 10.1016/j.critrevonc.2019.08.009
pubmed: 31675543
Scirocchi F, Strigari L, Di Filippo A, Napoletano C, Pace A, Rahimi H, et al. Soluble PD-L1 as a prognostic factor for immunotherapy treatment in solid tumors: systematic review and meta-analysis. Int J Mol Sci. 2022;23:14496.
doi: 10.3390/ijms232214496
pubmed: 36430974
pmcid: 9696773
Zizzari IG, Di Filippo A, Scirocchi F, Di Pietro FR, Rahimi H, Ugolini A, et al. Soluble immune checkpoints, gut metabolites and performance status as parameters of response to nivolumab treatment in NSCLC patients. J Pers Med. 2020;10:208.
doi: 10.3390/jpm10040208
pubmed: 33158018
pmcid: 7712566
Sanmamed MF, Perez-Gracia JL, Schalper KA, Fusco JP, Gonzalez A, Rodriguez-Ruiz ME, et al. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. Annal Oncol. 2017;28:1988.
doi: 10.1093/annonc/mdx190
Zhao Y, Jia S, Zhang K, Zhang L. Serum cytokine levels and other associated factors as possible immunotherapeutic targets and prognostic indicators for lung cancer. Front Oncol. 2023;13:1064616.
doi: 10.3389/fonc.2023.1064616
pubmed: 36874133
pmcid: 9977806
Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, et al. Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat Commun. 2017;8:592.
doi: 10.1038/s41467-017-00608-2
pubmed: 28928380
pmcid: 5605517
Zizzari IG, Napoletano C, Di Filippo A, Botticelli A, Gelibter A, Calabrò F, et al. Exploratory pilot study of circulating biomarkers in metastatic renal cell carcinoma. Cancers. 2020;12:2620.
doi: 10.3390/cancers12092620
pubmed: 32937860
pmcid: 7563741
Zizzari IG, Napoletano C, Botticelli A, Caponnetto S, Calabrò F, Gelibter A, et al. TK inhibitor pazopanib primes DCs by downregulation of the β-catenin pathway. Cancer Immunol Res. 2018;6:711.
doi: 10.1158/2326-6066.CIR-17-0594
pubmed: 29700053
Botticelli A, Zizzari IG, Scagnoli S, Pomati G, Strigari L, Cirillo A, et al. The role of soluble LAG3 and soluble immune checkpoints profile in advanced head and neck cancer: a pilot study. J Pers Med. 2021;11:651.
doi: 10.3390/jpm11070651
pubmed: 34357118
pmcid: 8304359
Machiraju D, Wiecken M, Lang N, Hülsmeyer I, Roth J, Schank TE, et al. Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients. Oncoimmunology. 2021;10:1926762.
doi: 10.1080/2162402X.2021.1926762
pubmed: 34104542
pmcid: 8158029
Kikuchi H, Maishi N, Annan DA, Alam MT, Dawood RIH, Sato M, et al. Chemotherapy-induced IL8 upregulates MDR1/ABCB1 in tumor blood vessels and results in unfavorable outcome. Cancer Res. 2020;80:2996.
doi: 10.1158/0008-5472.CAN-19-3791
pubmed: 32536602
Schauer T, Henriksson A, Strandberg E, Lindman H, Berntsen S, Demmelmaier I, et al. Pre-treatment levels of inflammatory markers and chemotherapy completion rates in patients with early-stage breast cancer. Int J Clin Oncol. 2023;28:89.
doi: 10.1007/s10147-022-02255-0
pubmed: 36269530
Sanmamed MF, Perez-Gracia JL, Schalper KA, Fusco JP, Gonzalez A, Rodriguez-Ruiz ME, et al. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. Ann Oncol. 2017;28:1988.
doi: 10.1093/annonc/mdx190
pubmed: 28595336
pmcid: 5834104
Széles A, Fazekas T, Váncsa S, Váradi M, Kovács PT, Krafft U, et al. Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis. Cancer Immunol Immunother. 2023;72:1061.
doi: 10.1007/s00262-022-03328-9
pubmed: 36385210
Bronte G, Petracci E, De Matteis S, Canale M, Zampiva I, Priano I, et al. High levels of circulating monocytic myeloid-derived suppressive-like cells are associated with the primary resistance to immune checkpoint inhibitors in advanced non small cell lung cancer: an exploratory analysis. Front Immunol. 2022;13: 866561.
doi: 10.3389/fimmu.2022.866561
pubmed: 35493483
pmcid: 9043492
Koh J, Kim Y, Lee KY, Hur JY, Kim MS, Kim B, et al. MDSC subtypes and CD39 expression on CD8+ T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLC. Eur J Immunol. 2020;50:1810.
doi: 10.1002/eji.202048534
pubmed: 32510574
pmcid: 7689686
Zhou X, Fang D, Liu H, Ou X, Zhang C, Zhao Z, et al. PMN-MDSCs accumulation induced by CXCL1 promotes CD8+ T cells exhaustion in gastric cancer. Cancer Lett. 2022;532: 215598.
doi: 10.1016/j.canlet.2022.215598
pubmed: 35176418
Chen J, Chen YJ, Jiang N, Xu JL, Liang ZM, Bai MJ, et al. Neutrophil-to-apolipoprotein A1 ratio predicted overall survival in hepatocellular carcinoma receiving transarterial chemoembolization. Oncologist. 2021;26: e1434.
doi: 10.1002/onco.13743
pubmed: 33675070
pmcid: 8342583
Yamauchi Y, Safi S, Blattner C, Rathinasamy A, Umansky L, Juenger S, et al. Circulating and tumor myeloid-derived suppressor cells in resectable non-small cell lung cancer. Am J Respir Crit Care Med. 2018;198:777.
doi: 10.1164/rccm.201708-1707OC
pubmed: 29617574
Kluger HM, Zito CR, Barr ML, Baine MK, Chiang VL, Sznol M, et al. Characterization of PD-L1 expression and associated T cell infiltrates in metastatic melanoma samples from variable anatomic sites. Clin Cancer Res. 2015;21:3052.
doi: 10.1158/1078-0432.CCR-14-3073
pubmed: 25788491
pmcid: 4490112
Krieg C, Nowicka M, Guglietta S, Schindler S, Hartmann FJ, Weber LM, et al. High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nat Med. 2018;24:144.
doi: 10.1038/nm.4466
pubmed: 29309059
Devi-Marulkar P, Fastenackels S, Karapentiantz P, Goc J, Germain C, Kaplon H, et al. Regulatory T cells infiltrate the tumor-induced tertiary lymphoïd structures and are associated with poor clinical outcome in NSCLC. Commun Biol. 2022;5:1416.
doi: 10.1038/s42003-022-04356-y
pubmed: 36566320
pmcid: 9789959